Tolebrutinib in multiple sclerosis: a pooled look that is still preliminary

Design

Systematic review and random-effects meta-analysis

Population

Four RCTs and one extension study of tolebrutinib in multiple sclerosis

Primary outcome

Confirmed disability progression, MRI activity and safety

Effect

Pooled progression 18.4% at ≥3 months, 14.1% at ≥6 months; serious adverse events 11.3%

A systematic review pooled four publications covering four randomised trials and one extension study of tolebrutinib, an oral brain-penetrant Bruton's tyrosine kinase inhibitor, in multiple sclerosis, searched to February 2026.

The authors report that tolebrutinib reduced confirmed disability progression in non-relapsing secondary progressive multiple sclerosis and reduced MRI inflammatory activity against placebo in earlier-phase relapsing disease. Pooled rates of progression on the drug were 18% at three months and 14% at six months. Adverse events of any kind were reported in 76%, serious adverse events in 11%, and discontinuation for adverse events in 4%; raised liver enzymes were among the safety outcomes reviewed.

The authors themselves call the evidence preliminary. The pooled figures largely describe outcomes on the drug rather than direct comparisons, the trials differed in population and comparator, and four studies is a thin base. The significance is that progressive multiple sclerosis without relapses has very few options, and this class targets the smouldering inflammation behind it. Its regulatory status and place against existing therapies should be checked before discussing it with patients.

• Tell patients with non-relapsing progressive multiple sclerosis that BTK inhibitors are being studied for their form of disease.
• Do not use this pooled analysis to compare tolebrutinib with established disease-modifying therapies.
• Expect liver monitoring to be part of any future use of this class.
• Consider trial referral for patients with progression independent of relapses.

Why it matters

Progressive multiple sclerosis without relapses has had few options, and this class aims at what drives it.

Don't overread it

Four studies pooled into single-arm rates cannot establish comparative efficacy.

The statistics, in plain English

The pooled progression rates are proportions on the drug, with wide intervals (about 10% to 32% at three months), not comparisons against placebo. That is why they describe the experience on the drug but cannot measure how much it helps.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.